Onyx (, which develops cancer drugs and treatments, said Monday that Amgen's takeover bid of $120 a share undervalued the company. Onyx stock closed Friday at $86.82. )
"We are actively exploring the potential to combine Onyx with another company as an option to create additional value for Onyx shareholders," said Onyx CEO N. Anthony Coles.
Shares of Onyx rose more than 6% last week on news of Amgen's offer. Overall, the stock has increased nearly 36% since last year.
Amgen (Fortune 500) is a major player in biopharmaceuticals, and manufactures drugs for many conditions, including ones that counteract the effects of cancer treatments. ,
|Five things you didn't know about Bernie Madoff's epic scam|
|Teen millionaire helping Yahoo become cool again|
|Obamacare: 365,000 have signed up for insurance on exchanges|
|What the budget deal doesn't do|
|Stocks falter as budget deal raises taper risk|